TW202246514A - 用於在疫苗接種期間增強t細胞之促發作用之病毒構築體 - Google Patents

用於在疫苗接種期間增強t細胞之促發作用之病毒構築體 Download PDF

Info

Publication number
TW202246514A
TW202246514A TW111104426A TW111104426A TW202246514A TW 202246514 A TW202246514 A TW 202246514A TW 111104426 A TW111104426 A TW 111104426A TW 111104426 A TW111104426 A TW 111104426A TW 202246514 A TW202246514 A TW 202246514A
Authority
TW
Taiwan
Prior art keywords
acid sequence
amino acid
peptide
seq
rmva
Prior art date
Application number
TW111104426A
Other languages
English (en)
Chinese (zh)
Inventor
瑪莉 喬 豪瑟
阿爾班 多米
葛利爾 古蒂爾瑞茲
詹姆士 潘努奇
賓內亞卡 寇崔亞
提摩西 法瑞茲
彼得 布昂坦普
賽西歐 布朗尼
Original Assignee
美商吉奧瓦科斯公司
美商里多公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商吉奧瓦科斯公司, 美商里多公司 filed Critical 美商吉奧瓦科斯公司
Publication of TW202246514A publication Critical patent/TW202246514A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111104426A 2021-02-02 2022-02-07 用於在疫苗接種期間增強t細胞之促發作用之病毒構築體 TW202246514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144834P 2021-02-02 2021-02-02
US63/144,834 2021-02-02

Publications (1)

Publication Number Publication Date
TW202246514A true TW202246514A (zh) 2022-12-01

Family

ID=82741782

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104426A TW202246514A (zh) 2021-02-02 2022-02-07 用於在疫苗接種期間增強t細胞之促發作用之病毒構築體

Country Status (12)

Country Link
US (1) US20240344082A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288076A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505274A (cg-RX-API-DMAC7.html)
KR (1) KR20240001116A (cg-RX-API-DMAC7.html)
CN (1) CN117177763A (cg-RX-API-DMAC7.html)
AU (1) AU2022215566A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015467A2 (cg-RX-API-DMAC7.html)
CA (1) CA3206004A1 (cg-RX-API-DMAC7.html)
IL (1) IL304805A (cg-RX-API-DMAC7.html)
MX (1) MX2023009008A (cg-RX-API-DMAC7.html)
TW (1) TW202246514A (cg-RX-API-DMAC7.html)
WO (1) WO2022169895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533785B (zh) * 2020-02-11 2022-03-08 北京市肿瘤防治研究所 靶向免疫检查点tim3结合肽及其应用
CA3167052A1 (en) 2020-02-14 2021-08-19 Mary Jo Hauser Vaccines and uses thereof to induce an immune response to sars-cov2
WO2024206243A1 (en) * 2023-03-24 2024-10-03 Geovax. Inc. Pan-betacoronavirus vaccines and uses thereof
WO2025072383A1 (en) * 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
CN117904069B (zh) * 2024-01-04 2025-07-15 华中农业大学 VirEN蛋白介导的DNA拼接和基因编辑方法
GB202409284D0 (en) * 2024-06-27 2024-08-14 Univ Oxford Innovation Ltd Mrna platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
UA82479C2 (uk) 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
DK2402451T3 (en) 2006-08-25 2018-06-25 The Government Of The Us Secretary Department Of Health And Human Services Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
US20100305002A1 (en) 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US9884075B2 (en) * 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
DK3552615T3 (da) * 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
DK3512536T3 (da) 2016-09-15 2020-11-23 Leidos Inc Pd-1-peptidinhibitorer
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
EP3630807B1 (en) 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
US20210155955A1 (en) * 2018-04-11 2021-05-27 Cancer Targeting Systems, Inc. Therapeutic constructs for treating cancer
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US12559526B2 (en) * 2018-10-15 2026-02-24 The Regents Of The University Of California Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins
CN115397998A (zh) 2020-02-03 2022-11-25 希望之城 由天然或合成dna产生的基于痘病毒的载体及其用途

Also Published As

Publication number Publication date
AU2022215566A1 (en) 2023-08-17
JP2024505274A (ja) 2024-02-05
EP4288076A4 (en) 2025-01-22
KR20240001116A (ko) 2024-01-03
WO2022169895A1 (en) 2022-08-11
IL304805A (en) 2023-09-01
AU2022215566A9 (en) 2025-01-30
MX2023009008A (es) 2023-10-05
EP4288076A1 (en) 2023-12-13
BR112023015467A2 (pt) 2023-10-10
US20240344082A1 (en) 2024-10-17
CA3206004A1 (en) 2022-08-11
CN117177763A (zh) 2023-12-05

Similar Documents

Publication Publication Date Title
US20240344082A1 (en) Viral constructs for use in enhancing t-cell priming during vaccination
CN110234346B (zh) 新的对抗寨卡病毒的疫苗和用于对抗寨卡病毒的dna抗体构建体的组合
CA3179319A1 (en) Enhanced immunogenic dna/rna compositions and methods
AU2016355468B2 (en) CMV vectors comprising microRNA recognition elements
WO2017152042A2 (en) Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
EP3612556B1 (en) Improved lamp constructs
WO2018161092A1 (en) Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
JP7670705B2 (ja) 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用
CN109641044A (zh) 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
CN119698292A (zh) 用于递送猴痘抗原的rna组合物和相关方法
WO2022103929A2 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
JP2025157424A (ja) 腫瘍関連抗原特異的t細胞応答
US20170258892A1 (en) Compositions and methods to treat aids
HK40102234A (en) Viral constructs for use in enhancing t-cell priming during vaccination
KR20240019135A (ko) 작제물과 면역자극 화합물의 공동발현
US20040131598A1 (en) Cancer therapy
WO2026085259A1 (en) Single-dose mva vaccines for protection against orthopoxvirus
HK40123095A (en) Improved lamp constructs
HK40014081B (en) Improved lamp constructs
HK40014081A (en) Improved lamp constructs
HK40014682B (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus